Nikola Corporation has filed a prospectus supplement on June 20, 2024, to update and supplement information from its previous prospectus dated July 17, 2020. The supplement includes details from a current report filed with the SEC on the same date. It pertains to the issuance of up to 23,890,000 shares of common stock, which includes shares issuable upon the exercise of warrants from a private placement and initial public offering of VectoIQ. Additionally, the supplement covers the offer and sale of up to 53,390,000 shares of common stock by selling securityholders, which also includes shares that may be issued upon the exercise of private warrants. On June 18, 2024, Nikola's common stock closed at $0.4809 and is listed on the Nasdaq Global Select Market under the symbol 'NKLA...Show More

Nikola Corporation has filed a prospectus supplement on June 20, 2024, to update and supplement information from its previous prospectus dated July 17, 2020. The supplement includes details from a current report filed with the SEC on the same date. It pertains to the issuance of up to 23,890,000 shares of common stock, which includes shares issuable upon the exercise of warrants from a private placement and initial public offering of VectoIQ. Additionally, the supplement covers the offer and sale of up to 53,390,000 shares of common stock by selling securityholders, which also includes shares that may be issued upon the exercise of private warrants. On June 18, 2024, Nikola's common stock closed at $0.4809 and is listed on the Nasdaq Global Select Market under the symbol 'NKLA'. Furthermore, the company's stockholders approved a reverse stock split at the annual meeting on June 5, 2024, which was later set by the Board at a 1-for-30 ratio, effective June 24, 2024. Post-split, the common stock will trade on Nasdaq under the same symbol with a new CUSIP number. The reverse stock split will result in every thirty issued shares being reclassified into one share, with no fractional shares issued. Adjustments will be made to outstanding equity awards, warrants, and convertible notes. The authorized shares of common stock will also be reduced from 1,600,000,000 to 1,000,000,000. The reverse stock split is expected to uniformly affect all stockholders and will not alter any stockholder's percentage ownership interest, except for changes due to fractional share treatment.